Programlı hücre ölümünün kalp yetmezliğindeki yeri

ÖZTÜRK, Melek; TÜRKOĞLU, Çavlan; SÜSLEYİCİ DUMAN, BELGİN

Programlı hücre ölümünün kalp yetmezliğindeki yeri

BELGİN SÜSLEYİCİ DUMAN, (Kadir Has Üniversitesi, Tıp Fakültesi, Tıbbi Biyoloji ve Genetik Anabilim Dalı, İstanbul, Türkiye)

Çavlan TÜRKOĞLU, (Kadir Has Üniversitesi, Tıp Fakültesi, Kardiyoloji Anabilim Dalı, İstanbul, Türkiye)

Melek ÖZTÜRK (İstanbul Üniversitesi, Cerrahpaşa Tıp Fakültesi, Tıbbi Biyoloji ve Genetik Anabilim Dalı, İstanbul, Türkiye)

Türkiye Klinikleri Tıp Bilimleri Dergisi

3 0

Yıl: 2005 Cilt: 25 Sayı: 1 Sayfa Aralığı: 85 - 92 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022

Programlı hücre ölümünün kalp yetmezliğindeki yeri

Öz:

Günümüzde insidansı giderek artan kalp yetersizliğinde programlı hücre ölümü olarak bilinen apoptozun moleküler ve biyokimyasal mekanizması henüz tam olarak aydınlatılamamıştır. Apoptoz aktif hücre içi haberleşme, hücreler arası yüzey teması kaybı, hücre büzüşmesi, DNA fragmantasyonu ve fagositoz ile karakterizedir. Apoptozun kalp yetersizliğinin fizyolojik ve patofizyolojik süreçlerinde önemli görevler üstlendiği mevcut bilgiler ile desteklenmektedir. Kalp yetersizliğinde kardiyomiyosit apoptozunu tetikleyen pek çok faktör bulunmaktadır. Ancak apoptotik süreçteki patofizyolojik uyaranlar ve etki mekanizmaları hakkında yanıt bekleyen sorular vardır. Bu nedenle apoptozu önlemeye yönelik terapide doğru hedefleme için, apoptoz inhibisyonunun kalp yetersizliğini geciktirdiği ya da önlediği kesin olarak bilinmediğinden ileri düzeyde moleküler ve farmokogenomik çalışmalara ihtiyaç duyulmaktadır.

Anahtar Kelime: Hücre ölümü Apoptoz Kalp yetmezliği, konjestif

Konular: Hücre ve Doku Mühendisliği Hücre Biyolojisi

Programmed cell death in heart failure: Review

Öz:

The molecular and biochemical mechanisms of programmed cell death, also known as apoptosis, have not yet to be fully elucidated. Apoptosis is characterized by active intracellular communication, loss of cellular attachment, cell shrinkage, DNA fragmentation and phagocytosis. Recently accumulated evidence indicates that apoptosis is involved in both physiological and pathophysiological processes of heart failure. Many factors have been identified that induce cardiomyocyte apoptosis during heart failure. However, many questions remain to be answered regarding the pathophysiological triggers of apoptosis and their mechanisms. As such, due to the incipient state of research regarding the question as to whether apoptotic inhibition delays or prevents heart failure, it appears advanced molecular and pharmaco-genomic studies will be essential in identifying potential targets in prospective therapies for the prevention of apoptosis.

Anahtar Kelime: Heart Failure, Congestive Cell Death Apoptosis

Konular: Hücre ve Doku Mühendisliği Hücre Biyolojisi

Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Bibliyografik

1. Colucci WS, Braunwald E. Pathophysiology of heart failure. In: Braunwald E, Zipes DP, Libby P, eds. Heart Disease. A Textbook of Cardiovascular Medicine. 6th ed. Philadelphia: WB Saunders; 2001. p.503.
2. Rumberger JA, Murphy JG. Left ventricular systolic function. In: Murphy JG, ed. Mayo Clinic Cardiology Review. 2nd ed. Philadelphia: Lippincott Williams Wilkins; 2000 p.27.
3. Brady PA, Terzic A. Essential of cellular heart failure. In: Murphy JG, ed. Mayo Clinic Cardiology Review. 2nd ed. Philadelphia: Lippincott Williams Wilkins; 2000. p.93.
4. Davies CH, Harding SE, Poole-Wilson PA. Cellular mechanisms of contractile dysfunction in human heart failure. Eur Heart J 1996;17:189-98.
5. Niimura H, Bachinski LL, Sangwatanaroj S, et al. Mutations in the gene for cardiac myosin-binding protein C and late-onset familial hypertrophic cardiomyopathy. N Eng J Med 1998;338:1248-57.
6. Erkan M, Yılmazer N. Apoptoz ve tıptaki önemi. Düzce Tıp Fakültesi Dergisi 2001;3:43-9.
7. MacLellan WR, Schneider MD. Death by design. Programmed cell death in cardiovascular biology and disease. CircResl997;81:137-44.
8. Kültürsay H, Kayıkçıoğlu M. Apoptozis ve kardiyovasküler hastalıklar. Anadolu Kardiyol Derg 2002;2: 323-9.
9. Yaoita H, Ogawa K, Maehara K, Maruyama Y. Apoptosis in relevant clinical situations: Contribution of apoptosis in myocardial infarction. Cardiovasc Res 2000;45:630-41.
10. Sabbah HN. Apoptotic cell death in heart failure. Cardiovasc Res 2000;45:704-12.
11. Hockenbery DM, Oltvai ZN, Yin,-XM, Milliman CL, Korsmeyer SJ. Bcl-2 functions in an antioxidant pathway to prevent apoptosis. Cell 1993;75:241-51.
12. Elsasser A, Suzuki K, Schaper J. Unresolved issues re-. garding the role of apoptosis in the pathogenesis of , ischemic injury and heart failure. J Mol Cell Cardiol 2000; 32:711-24.
13. Schwartz K, Mercadier JJ. Molecular and cellular biology of heart failure. Curr Opin Cardiol 1996; 11:227-36.
14. Kannel WB. Need and prospects for prevention of cardiac failure, Eur J Clin Pharmacol 1996;49(Suppl 1):S3-9.
15. Anversa P, Leri A, Beltrami CA, Guerra S, Kajstura J. Myocyte death and growth in the failing heart. Lab Invest 1998;78:767-86.
16. Haunstetter A, Izumo S. Apoptosis: Basic mechanisms and implications for cardiovascular disease. Circ Res 1998;82:1111-29. confidence intervals while studying a sample of a given population. In order to obtain valid and reproducible estimates of the “truth”, researchers should be aware of potential errors and their identifying characteristics and attempt to assess the best ways of avoiding such biases, regardless of the specific objectives and/or sample size of a given study.
17. Kerr JF, Wyllie AH, Currie AR. Apoptosis: A basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972;26:239-57.
18. Ellis HM, Horvitz HR. Genetic control of programmed cell death in the nematode C. elegans. Cell 1986;44:817-29.
19. Hengartner MO, Horvitz HR. C. elegans cell survival gene ced-9 encodes a functional homolog of the mammalian proto-oncogene bcl-2. Cell 1994;76:665-76.
20. Horvitz HR, Shaham S, Hengartner MO. The genetics of programmed cell death in the nematode Caenorhabditis elegans. Cold Spring Harb Symp Quant Biol 1994;59:377-85.
21. Öztürk F. Apopitoz. İnönü Üniversitesi Tıp Fakültesi Dergisi 2002;9:143-8.
22. Öktem S, Özhan MH, Özol D. Apoptozisin önemi. Toraks Dergisi 2001;2:91-5.
23. Chen HH, Lainchbury JG, Harty GJ, Burnett JC Jr. Maximizing the natriuretic peptide system in experimental heart failure: Subcutaneous brain natriuretic peptide and acute vasopeptidase inhibition. Circulation 2002;105:999-1003.
24. Gullestad L, Aass H, Fjeld JG, et al. Immunomodulating therapy with intravenous immunoglobulin in patients with chronic heart Vailure. Circulation 2001; 103:220-5.
25. Aukrust P, Froland SS, Liabakk NB, et al. Release of cytokines, soluble cytokine receptors, and interleukin-1 receptor antagonist after intravenous immunoglobulin administration in vivo. Blood 1994;84:2136-43.
26. Louis A, Cleland JG, Crabbe S, et al. Clinical Trials Update: CAPRICORN, COPERNICUS, MIRACLE, STAF, RITZ-2, RECOVER and RENAISSANCE and cachexia and cholesterol in heart failure. Highlights of the Scientific Sessions of the American College of Cardiology, 2001. Eur J Heart Fail 2001;3:381-7.
27. Mills RM, LeJemtel TH, Horton DP, et al. Sustained hemodynamic effects of an infusion of nesiritide (human b-type natriuretic peptide) in heart failure: A randomized, double-blind, placebo-controlled clinical trial. Natrecor Study Group. J Am Coll Cardiol 1999;34:155-62.
28. Bozkurt B, Kribbs SB,' Clubb FJ Jr, et al. Pathophysiologically relevant concentrations of tumor necrosis factor-alpha promote progressive left ventricular dysfunction and remodeling in rats. Circulation 1998;97:1382-91.
29. Hockenbery D, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ. Bcl-2 is an inner mitochondrial membrane protein that blocks^ programmed cell death. Nature 1990; 348:334-6;
30. Allsopp TE, Wyatt S, Paterson HF, Davies AM. The proto-oncogene bcl-2 can selectively rescue neurotrophic factor-dependent neurons from apoptosis. Cell 1993; 73:295-307.
31. Cheng W, Kajstura J, Nitahara JA, et al. Programmed myocyte cell death affects the viable myocardium after infarction in rats. Exp Cell Res 1996; 226:316-27.
32. Olivetti G, Abbi R, Quaini F, et al. Apoptosis in the failing human heart. N Engl J Med 1997;336:1131-41.
33. Clarke AR, Purdie CA, Harrison DJ, et al. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 1993 ;362:849-52.
34. Li Z, Bing OH, Long X, Robinson KG, Lakatta EG. Increased cardiomyocyte apoptosis during the transition to heart failure in the spontaneously hypertensive rat. Am J Physiol 1997 ;272:H2313-9.
35. Bialik S, Geenen DL, Sasson IE, et al. The caspase family of cysteine proteases mediate cardiac myocyte apoptosis during myocardial infarction (Abstract). Circulation 1997; 96:1552.
36. Black SC, Huang JQ, Rezaiefar P, et al. Co-localization of the cysteine protease caspase-3 with apoptotic myocytes after in vivo myocardial ischemia and reperfusion in the rat. J Mol Cell Cardiol 1998;30:733-42.
37. Goldman BI, Fisher CA, Johnston E, et al. Caspase-3 expression in failing human hearts (Abstract). Circulation 1998;98:I-75.
38. Goldstein P. Controlling cell death. Science 1997; 275:1081-2.
39. Bialik S, Cryns V, Drincic A, Srinivasan A, Kitsis RN. Cytochrome c release from the mitochondria precedes caspase activation in apoptotic myocytes during ischemia (Abstract). Circulation 1998;98:I-462.
40. Shimizu S, Eguchi Y, Kamiike W, Matsuda H, Tsujimoto Y. Bcl-2 expression prevents activation of the ICE prote- ase cascade. Oncogene 1996; 12:2251-7.
41. Sabbah HN, Sharov V, Riddle JM, Kono T, Lesch M, Goldstein S. Mitochondrial abnormalities in myocardium of dogs with chronic heart failure. J Mol Cell Cardiol 1992;24:1333-47.
42. Sharov VG, Goussev A, Lesch M, Goldstein S, Sabbah HN. Abnormal mitochondrial function in myocardium of dogs with chronic heart failure. J Mol Cell Cardiol 1998; 30:1757-62.
43. Okuyama M, Yamaguchi S, Nozaki N, Yamaoka M, Shirakabe M, Tomoike H. Serum levels of soluble form of Fas molecule in patients with congestive heart failure. Am J Cardiol 1997;79:1698-701.
44. Nishigaki K, Minatoguchi S, Seishima M, et al. Plasma Fas ligand, an inducer of apoptosis, and plasma soluble Fas, an inhibitor of apoptosis, in patients with chronic congestive heart failure. J Am Coll Cardiol 1997;29:1214-20.
45. Yamaguchi S, Yamaoka M, Okuyama M. Elevated/circulating levels of soluble Fas ligand in patients with congestive heart'failure. Circulation 1997;96:I-150.
46. Evan GI, Brown L, Whyte M, Harrington E. Apoptosis and the cell cycle. Curr Opin Cell Biol 1995;7:825-34.
47. Meikrantz W, Schlegel R. Apoptosis and the cell cycle. J CellBiochem 1995;58:160-74.
48. Kirshenbaum LA, Abdellatif M, Chakraborty S, Schneider MD. Human E2F-1 reactivates cell cycle progression in ventricular myocytes and represses cardiac gene transcription. DevBiol 1996;179:402-11.
49. King KL, Cidlowski JA. Cell cycle and apoptosis: Common pathways to life and death. J Cell Biochem 1995; 58:175-80.
50. Kubota T, Miyagishima M, Bounoutas GS, McTiernan CF, Feldman AM. Overexpression of tumor necrosis factor-a activates the expression of multiple members of the apoptosis pathway in transgenic mice (Abstract). Circulation 1998;98:I-462.
51. Reiss K, Cheng W, Giordano A, et al. Myocardial infarction is coupled with the activation of cyclins and cyclindependent kinases in myocytes. Exp Cell Res 1996;225:44-54.
52. Liu Y, Cigola E, Cheng W, et al. Myocyte nuclear mitotic division and programmed myocyte cell death characterize the cardiac myopathy induced by rapid ventricular pacing in dogs. Lab Invest 1995;73:771-87.
53. Jaskulski D, Gatti C, Travali S, Calabretta B, Baserga R. Regulation of the proliferating cell nuclear antigen cyclin and thymidine kinase mRNA levels by growth factors. J Biol Chem 1988;263:10175-9.
54. Muller DW. The role of proto-oncogenes in coronary restenosis. Prog Cardiovasc Dis 1997;40:117-28.
55. Burton PB, Yacoub MH, Barton PJ. Cyclin-dependent kinase inhibitor expression in human heart failure. A com- parison with fetal development. Eur Heart J 1999;20:604-11.
56. Anversa P, Kajstura J. Ventricular myocytes are not terminally differentiated in the adult mammalian heart. Circ Res 1998;83:1-14.
57. Liu Y, Kitsis RN. Induction of DNA synthesis and apoptosis in cardiac myocytes by E1A oncoprotein. J Cell Biol 1996;133:325-34.
58. Gottlieb RA, Burleson KO, Kloner RA, Babior BM, Engler RL. Reperfusion injury induces apoptosis in rabbit cardiomyocytes. J Clin Invest 1994;94:1621-8.
59. Tanaka M, Ito H, Adachi S, et al. Hypoxia induces apoptosis with enhanced expression of Fas antigen messenger RNA in cultured neonatal rat cardiomyocytes. Circ Res 1994;75:426-33.
60. Long X, Boluyt MO, Hipolito ML, et al. p53 and the hypoxia-induced apoptosis of cultured neonatal rat cardiac myocytes. J Clin Invest 1997;99:2635-43.
61. Kajstura J, Cigola E, Malhotra A, et al. Angiötensin II induces apoptosis of adult ventricular myocytes in vitro. J Mol Cell Cardiol 1997;29:859-70.
62. Communal C, Singh K, Pimentel DR, Colucci Ws. Norepinephrine stimulates apoptosis in adult rat ventricular myocytes by activation of the beta-adrenergic pathway/Circulation 1998;98:1329-34.
63. Krown KA, Page MT, .Nguyen C, et al. Tumor necrosis factor alpha-induced apoptosis in cardiac myocytes. Involvement of the sphingolipid signaling cascade in cardiac cell death. J Clin Invest 1996;98:2854-65.
64. Bozkurt B, Shan K, Seta Y, Oral H, Mann DL. Tumor necrosis factor-a and tumor necrosis factor receptors in human heart failure. Heart Failure Rev 1996;1:211-9.
65. Sabbah HN, Sharov VG, Goussev A, Goldstein S. Long term therapy with metoprolol attenuates cardiomyocyte apoptosis in dogs with heart failure. Circulation 1998- 98:1-364.
66. Long X, Crow MT, Lakatta EG. Ice-related proteases are involved in hypoxia-induced apoptosis in cardiac myocytes. Circulation 1997;96:I737.
67. Webster KA, Discher DJ, Bishopric NH. Induction and nuclear accumulation of fos and jun proto-oncogenes in hypoxic cardiac myocytes. J Biol Chem 1993;268:16852-8.
68. Askew DS, Ashmun RA, Simmons BC, Cleveland JL. Constitutive c-myc expression in an IL-3-dependent myeloid cell line suppresses cell cycle arrest and accelerates apoptosis. Oncogene 1991;6:1915-22.
69. Amati B, Littlewood TD, Evan GI, Land H. The c-Myc protein induces cell cycle progression and apoptosis through dimerization with Max. EMBO J 1993; 12:5083-7.
70. Haunstetter A, Izumo S. Toward antiapoptosis as a new treatment modality. Circ Res 2000;86:371-6.
71. Yaoita H, Ogawa K, Maehara K, Maruyama Y. Attenuation of ischemia/reperfusion injury in rats by a caspase inhibitor. Circulation 1998;97:276-81.
72. Holly TA, Drincic A, Byun Y, et al. Caspase inhibition reduces myocyte cell death induced by myocardial ischemia mia and reperfusion in vivo. J Mol Cell Cardiol 1999;31:1709-15.
73. Goussev A, Sharov VG, Shimoyama H, et al. Effects of ACE inhibition on cardiomyocyte apoptosis in dogs with heart failure. Am J Physiol 1998;275:H626-31.
74. Yue TL, Ma XL, Wang X, et al. Possible involvement of stress-activated protein kinase signaling pathway and Fas receptor expression in prevention of ischemia/reperfusioninduced cardiomyocyte apoptosis by carvedilol. Circ Res 1998;82:166-74.

APA	SÜSLEYİCİ DUMAN B, TÜRKOĞLU Ç, ÖZTÜRK M (2005). Programlı hücre ölümünün kalp yetmezliğindeki yeri. , 85 - 92.
Chicago	SÜSLEYİCİ DUMAN BELGİN,TÜRKOĞLU Çavlan,ÖZTÜRK Melek Programlı hücre ölümünün kalp yetmezliğindeki yeri. (2005): 85 - 92.
MLA	SÜSLEYİCİ DUMAN BELGİN,TÜRKOĞLU Çavlan,ÖZTÜRK Melek Programlı hücre ölümünün kalp yetmezliğindeki yeri. , 2005, ss.85 - 92.
AMA	SÜSLEYİCİ DUMAN B,TÜRKOĞLU Ç,ÖZTÜRK M Programlı hücre ölümünün kalp yetmezliğindeki yeri. . 2005; 85 - 92.
Vancouver	SÜSLEYİCİ DUMAN B,TÜRKOĞLU Ç,ÖZTÜRK M Programlı hücre ölümünün kalp yetmezliğindeki yeri. . 2005; 85 - 92.
IEEE	SÜSLEYİCİ DUMAN B,TÜRKOĞLU Ç,ÖZTÜRK M "Programlı hücre ölümünün kalp yetmezliğindeki yeri." , ss.85 - 92, 2005.
ISNAD	SÜSLEYİCİ DUMAN, BELGİN vd. "Programlı hücre ölümünün kalp yetmezliğindeki yeri". (2005), 85-92.

APA	SÜSLEYİCİ DUMAN B, TÜRKOĞLU Ç, ÖZTÜRK M (2005). Programlı hücre ölümünün kalp yetmezliğindeki yeri. Türkiye Klinikleri Tıp Bilimleri Dergisi, 25(1), 85 - 92.
Chicago	SÜSLEYİCİ DUMAN BELGİN,TÜRKOĞLU Çavlan,ÖZTÜRK Melek Programlı hücre ölümünün kalp yetmezliğindeki yeri. Türkiye Klinikleri Tıp Bilimleri Dergisi 25, no.1 (2005): 85 - 92.
MLA	SÜSLEYİCİ DUMAN BELGİN,TÜRKOĞLU Çavlan,ÖZTÜRK Melek Programlı hücre ölümünün kalp yetmezliğindeki yeri. Türkiye Klinikleri Tıp Bilimleri Dergisi, vol.25, no.1, 2005, ss.85 - 92.
AMA	SÜSLEYİCİ DUMAN B,TÜRKOĞLU Ç,ÖZTÜRK M Programlı hücre ölümünün kalp yetmezliğindeki yeri. Türkiye Klinikleri Tıp Bilimleri Dergisi. 2005; 25(1): 85 - 92.
Vancouver	SÜSLEYİCİ DUMAN B,TÜRKOĞLU Ç,ÖZTÜRK M Programlı hücre ölümünün kalp yetmezliğindeki yeri. Türkiye Klinikleri Tıp Bilimleri Dergisi. 2005; 25(1): 85 - 92.
IEEE	SÜSLEYİCİ DUMAN B,TÜRKOĞLU Ç,ÖZTÜRK M "Programlı hücre ölümünün kalp yetmezliğindeki yeri." Türkiye Klinikleri Tıp Bilimleri Dergisi, 25, ss.85 - 92, 2005.
ISNAD	SÜSLEYİCİ DUMAN, BELGİN vd. "Programlı hücre ölümünün kalp yetmezliğindeki yeri". Türkiye Klinikleri Tıp Bilimleri Dergisi 25/1 (2005), 85-92.